The main pathological features of IgAN are IgA or IgA-based immune complexes deposited in the mesangial area, accompanied by membrane cell proliferation and matrix increase.[1,2] Previous studies have shown that up to 40% of patients can progress to end-stage renal disease 5 to 25 years after diagnosis of IgAN.[3,4] Thus, early diagnosis and treatment are critical for delaying or blocking the progression of IgAN. Here, CD79A is linked to chronic kidney disease.